-- 週二下午晚些時候，醫療保健類股小幅走高，紐約證券交易所醫療保健指數和道富醫療保健精選行業SPDR ETF (XLV) 均上漲約0.4%。 iShares生物技術ETF (IBB) 上漲0.1%。 在公司新聞方面，Edgewise Therapeutics (EWTX) 股價飆升22%，此前Wedbush將該公司目標股價從32美元上調至46美元，並維持「跑贏大盤」評級。 輝瑞 (PFE) 第一季度業績超越分析師預期，其主要品牌強勁的需求抵消了新冠肺炎產品銷售疲軟的影響。輝瑞股價上漲0.9%。 默克 (MRK) 股價上漲0.6%。該公司週二表示，已完成對Terns Pharmaceuticals的收購，收購價格為每股53美元。 Scilex (SCLX) 股價週二下跌 3%，此前該公司表示，其子公司 ACEA Therapeutics 同意以 10 億美元的全股票交易將 ACEA Pharma 的 100% 股權轉讓給 Phoenix Asia (PHOE)。
Related Articles
Asia
Cofoe Medical Technology Nets HK$1 Billion From Hong Kong IPO Ahead of Debut
Cofoe Medical Technology (HKG:1187, SHE:301087) raised HK$1.01 billion in net proceeds from its initial public offering in Hong Kong.The offer price was set at HK$39.33 per H-share, according to a Tuesday after-market filing with the Hong Kong Stock Exchange.The China-based home care medical device provider offered 27 million H-shares in the global offering.The Hong Kong public offer was 399.08 times subscribed, with 2.7 million shares allocated, representing 10% of the total offering.The international offering was 3.4 times subscribed, with 24.3 million shares allocated, accounting for 90% of the total offering.Cornerstone investors, including Lens Technology (HK), Changsha Yufeng Technology, Vision Capital, and Panjing Harbourview Investment Fund, were allocated about 9.7 million shares in the international tranche, according to the filing.Cofoe Medical is scheduled to begin trading in Hong Kong on Wednesday, May 6.
$HKG:1187$SHE:301087
Insider Trading
Cytokinetics Insider Sold Shares Worth $270,795, According to a Recent SEC Filing
Fady Ibraham Malik, Executive Vice President, Research & Development, on May 05, 2026, sold 3,500 shares in Cytokinetics (CYTK) for $270,795. Following the Form 4 filing with the SEC, Malik has control over a total of 153,902 common shares of the company, with 153,902 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1061983/000106198326000051/xslF345X05/form4.xml
$CYTK
Mining & Metals
Correction: -- Pan American Silver Targets Up to US$1B in Shareholder Returns in 2026 Through Enhanced Shareholder Return Framework
$PAAS.TO